Mr. Daly served as Executive Vice President and Chief Commercial Officer at Incyte Corporation from 2012 to 2015. During his tenure, he was instrumental in re-accelerating the launch of Jakafi® and driving sustained growth.
Prior to joining Incyte, Mr. Daly worked for Amgen, Inc. for 10 years, holding multiple leadership positions. In his last role, Mr. Daly served as Senior Vice President, North America Commercial Operations, Global Marketing and Commercial Development. Previously, he served as Vice President and General Manager of Amgen’s Oncology Business Unit. His teams at Amgen were responsible for the successful launch of many products, including Aranesp®, Neulasta®, Vectibix®, Nplate®, Xgeva® and Prolia®.
Previously, Mr. Daly spent over 16 years with Glaxo Wellcome/GlaxoSmithKline (GSK) where he held roles of increasing responsibility, including Senior Vice President, General Manager, Respiratory and Anti-Infective Business Unit, and led the U.S. launch of Advair®.
He currently serves on the boards of directors of argenx SE, Chimerix Inc., Bellicum Pharmaceuticals, Inc. and Halozyme Therapeutics. Mr. Daly earned his B.S. in Pharmacy and M.B.A. from the University at Buffalo, The State University of New York.
What is James M. Daly's net worth?
The estimated net worth of James M. Daly is at least $107.29 thousand as of November 10th, 2025. Mr. Daly owns 4,041 shares of ACADIA Pharmaceuticals stock worth more than $107,289 as of December 5th. This net worth evaluation does not reflect any other investments that Mr. Daly may own. Learn More about James M. Daly's net worth.
How do I contact James M. Daly?
Has James M. Daly been buying or selling shares of ACADIA Pharmaceuticals?
Over the course of the past ninety days, James M. Daly has sold $671,100.00 in ACADIA Pharmaceuticals stock. Most recently, James M. Daly sold 30,000 shares of the business's stock in a transaction on Monday, November 10th. The shares were sold at an average price of $22.37, for a transaction totalling $671,100.00. Following the completion of the sale, the director now directly owns 4,041 shares of the company's stock, valued at $90,397.17. Learn More on James M. Daly's trading history.
Who are ACADIA Pharmaceuticals' active insiders?
Are insiders buying or selling shares of ACADIA Pharmaceuticals?
During the last year, insiders at the biopharmaceutical company sold shares 18 times. They sold a total of 110,884 shares worth more than $2,456,977.59. The most recent insider tranaction occured on November, 18th when EVP Mark C Schneyer sold 10,262 shares worth more than $243,106.78. Insiders at ACADIA Pharmaceuticals own 26.5% of the company.
Learn More about insider trades at ACADIA Pharmaceuticals. Information on this page was last updated on 11/18/2025.
